EDX110 Randomized Control Trial for Treatment of DFUs

Recruiting now · Not applicable

Conditions studied: Wound Heal, Diabetic Foot Ulcer

In brief

Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.

Key facts

Study ID

NCT07209358

Run by

ConvaTec Inc.

People needed

298

Starts

2025-10-30

Expected to finish

2026-12-31

Last updated by the study team

2025-12-17

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study.
• The participant must have an index ulcer meeting the following characteristics:
• Non-healing DFU defined as; at least 4 weeks prior to enrolment the ulcer has failed to progress on a healing trajectory.
• Full-thickness wound; defined as Wagner Diabetic Foot Ulcer Grade 1 - superficial ulcer of skin or subcutaneous tissue.
• Located on the anatomical foot; defined as distal to the medial or lateral malleolus.
• Presents with or without clinical signs of superficial infection. Infection is defined using International Working Group of the Diabetic Foot (IWGDF) PEDIS classification and for the purpose of inclusion infections must be PEDIS grade 1 (Mild); Infected: At least two of these items are present: Local swelling or induration Erythema >0.5 but <2 cm2 around the wound, Local tenderness or pain, Local increased warmth, Purulent discharge.
• Ulcer duration at randomization must be present for ≥1 month but less than <24 months in duration.
• Post-debridement wound area is ≥0.1 cm2 and ≤25 cm2.
• If two or more ulcers either mono or bilateral are present, the index ulcer must additionally be:
• The ulcer with the largest wound area, as long as it meets all other criteria.
• ≥3cm distance from any other ulcer on the affected limb
• Known history of type 1 or type 2 diabetes (confirmed by the subject's medical history).
• HgbA1c <12% (NGSP) OR 108 mmol/mol (IFCC) OR average blood glucose 298 mg/DL.
• Participant has adequate circulation to the affected extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grades 0-1 (no PAD to Mild PAD).
• Participants are required to have either.
• Ankle-Brachial Index (ABI) by Doppler: ≥0.6 OR Toe-Brachial Index (TBI) ≥ 0.5
• OR Dorsum transcutaneous oxygen test (TcPO2): >40 mm/Hg

You may not qualify if…

• Participants with wounds that have any of the following characteristics:
• Wagner Grade 2 - ulcers extend into tendon, bone, or capsule
• Grade 3 - deep ulcer with osteomyelitis, or abscess
• Grade 4 - partial foot gangrene
• Grade 5 - whole foot gangrene
• Infections that are classified as:
• PEDIS 3 (Moderate): Infection with no systemic manifestations and involving: Erythema extending ≥2 cm2 from the wound margin, and/or tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone).
• PEDIS 4 (Severe): All of the above in PEDIS 3 plus manifestations (of the systemic inflammatory response syndrome [SIRS]).
• In addition, any diabetic foot infections with; Confirmed underlying bone involvement (osteomyelitis) based on; imaging (plain X-ray, CT or MRI), clinical examination (exposed bone or positive probe to bone test) or culture/histopathology of a bone specimen
• OR Cellulitis/lymphangitis/soft tissue gas or necrotizing fasciitis originating from the wound site.
• Tunnelling, Cavity or undermining wounds.
• Known or suspected local skin malignancy at the site of the ulcer.
• A wound that is actively bleeding. This does not exclude enrollment once active bleeding has stopped (hemostasis).
• Gross Foot deformities that would interfere with proper off-loading or proper wound healing i.e. non-active charcot foot, rocker bottom foot, gross digital deformities.
• Active Charcot deformity.
• Wound duration >2 years.
• Participants receiving any of the following prior therapies. In the last 30 days:
• Has required systemic corticosteroids >10mg/kg/day OR
• Participant has required Chemoradiation (chemotherapy and/or radiation therapy) to treat cancer and is immunocompromised OR
• Participant is anticipated to require such medications during the study period.
• Study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g., Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g., OASIS® Wound Matrix, MatriStem Wound Matrix).
• Has undergone any amputation to the affected leg.
• Known hypersensitivity to constituents of the product.
• Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of, or compliance with the study protocol in the judgement of the Investigator.
• Women of childbearing age (women aged <55 years who have not undergone menopause) who are:

Where it is running

• Axentra Bio — Phoenix, Arizona, United States (enrolling)
• Clemente Clinical Research — Santa Ana, California, United States (enrolling)
• ILD Research Center — Vista, California, United States (enrolling)
• Futuro Clinical Trials — McAllen, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.